Pediatric allergy medications: review of currently available formulations

References

• Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006;368:733-43
   PubMed Web of Science ®Google Scholar
• Bousquet J, Ansotegui IJ, van Ree R, et al. European Union meets the challenge of the growing importance of allergy and asthma in Europe. Allergy 2004;59:1-4
   PubMed Web of Science ®Google Scholar
• Bousquet J, Ndiaye M, Ait-Khaled N, et al. Management of chronic respiratory and allergic diseases in developing countries. Focus on sub-Saharan Africa. Allergy 2003;58:265-83
   Google Scholar
• Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen) Allergy 2008;63(Suppl. 86):8-160
   Google Scholar
• Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case–control study. J Allergy Clin Immunol 2007;120:381-7
   PubMed Web of Science ®Google Scholar
• Blaiss M. Current concepts and therapeutic strategies for allergic rhinitis in school-age children. Clin Ther 2004;26:1876-89
   PubMed Web of Science ®Google Scholar
• Vuurman EF, van Veggle LM, Ulterwijk MM, et al. Seasonal AR and antihistamine effects on children's learning. Ann Allergy 1993;71:121-6
   PubMedGoogle Scholar
• Philip G, Nayak AS, Berger WE, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004;20:1549-58
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-17
   PubMed Web of Science ®Google Scholar
• Baena-Cagnani CE, Berger WE, Dubuske LM, et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol 2003;130:307-13
   PubMed Web of Science ®Google Scholar
• Berger WE, Schenkel EJ, Mansfield LE. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002;89:485-91
   PubMed Web of Science ®Google Scholar
• Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008;38:19-42
   PubMed Web of Science ®Google Scholar
• Bousquet J, van Cauwenberge P, Aït Khaled N, et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy 2006;61:1086-96
   PubMed Web of Science ®Google Scholar
• Price D, Bond C, Bouchard J, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis. Prim Care Respir J 2006;15:58-70
   PubMedGoogle Scholar
• van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy 2000;55:116-34
   PubMed Web of Science ®Google Scholar
• Dykewicz MS, Fineman S. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998;81:478-518
   PubMed Web of Science ®Google Scholar
• Lai L, Casale TB, Stokes J. Pediatric allergic rhinitis: treatment. Immunol Allergy Clin North Am 2005;25:283-99
   PubMed Web of Science ®Google Scholar
• Baena-Cagnani CE. Safety and tolerability of treatments for allergic rhinitis in children. Drug Saf 2004;27:883-98
   PubMed Web of Science ®Google Scholar
• McNeely W, Wiseman LR. Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis. Drugs 1998;56:91-114
   PubMed Web of Science ®Google Scholar
• Cutler DL, Banfield C, Melton B, et al. Safety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr Asthma Allergy Immunol 2006;19:146-53
   Google Scholar
• Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial AR after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000;105:e22
   PubMed Web of Science ®Google Scholar
• Skoner DP, Gentile D, Angelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with AR. Ann Allergy Asthma Immunol 2003;90:56-62
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Berger WE, Berkowitz RB, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal AR. J Allergy Clin Immunol 1999;104:107-14
   PubMed Web of Science ®Google Scholar
• Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997;19:1330-9
   PubMed Web of Science ®Google Scholar
• Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal AR. Pediatrics 1993;92:594-9
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Maurer M, Augustin M. Use of topical steroids is largely restricted by irrational emotional concerns in both patients and physicians. Allergy 2008;63:1560-1
   PubMed Web of Science ®Google Scholar
• Chervinsky P, Kunjibettu S, Miller DL, et al. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2007;99:69-76
   PubMed Web of Science ®Google Scholar
• Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 2007;62:1071-7
   PubMed Web of Science ®Google Scholar
• Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf 2007;30:317-26
   PubMed Web of Science ®Google Scholar
• Transgrud AJ, Whitaker AL, Small RE. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy 2002;22:1458-67
   PubMed Web of Science ®Google Scholar
• Mahr TA, Sheth KK, Boyle JM. Lack of efficacy and bothersome side effects decrease treatment adherence in children with allergic rhinitis. Presented at the American College of Allergy, Asthma and Immunology Annual Meeting; Dallas, TX; Nov 9–14, 2007
   Google Scholar
• Galant SP, Wilkinson R. Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options?. Biodrugs 2001;15:453-63
   PubMed Web of Science ®Google Scholar
• Meltzer EO. Treatment options for the child with allergic rhinitis. Clin Pediatr (Phila) 1998;37:1-10
   PubMed Web of Science ®Google Scholar
• Graf P. Rhinitis medicamentosa: a review of causes and treatment. Treat Respir Med 2005;4:21-9
   PubMedGoogle Scholar
• Taverner D, Latte J. Nasal decongestants for the common cold. Cochrane Database Syst Rev 2007;Jan 24;(1): CD001953
   Google Scholar
• Food and Drug Administration. FDA releases recommendations regarding use of over-the-counter cough and cold products: products should not be used in children under 2 years of age; evaluation continues in older populations [FDA news release]. Rockville, MD: Center for Drug Evaluation and Research, January 17, 2008. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116839.htm [Last accessed 3 June 2009]
   Google Scholar
• Statement from CHPA on the voluntary label updates to oral OTC children's cough and cold medicines [press release]Washington, DC: Consumer Healthcare Products Association, October 7, 2008. Available at: http://www.chpa-info.org/10_07_08_PedCC.aspx [Last accessed 3 June 2009]
   Google Scholar
• Legal requirements for the sale and purchase of drug products containing pseudoephedrine, ephedrine, and phenylpropanolamine [press release]. Washington, DC: US Food and Drug Administration, May 8, 2006. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm072423.htm [Last accessed 3 June 2009]
   Google Scholar
• Nasal decongestants get new sales restrictions [press release]. London, England: Medicines and Healthcare products Regulatory Agency, August 29, 2007. Available at: http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON2032216 [Last accessed 3 June 2009]
   Google Scholar
• Pseudoephedrine rescheduling – information for sponsors. Canberra, Australia: Australian Government Department of Health and Ageing Administration Therapeutic Goods Agency, September 15, 2008. Available at: http://www.health. gov.au/internet/main/publishing.nsf/Content/annual-report2007.htm [Last accessed 3 June 2009]
   Google Scholar
• Eccles R. Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse. Br J Clin Pharmacol 2007;63:10-14
   PubMed Web of Science ®Google Scholar
• Hengstmann JH, Goronzy J. Pharmacokinetics of 3H-phenylephrine in man. Eur J Clin Pharmacol 1982;21:335-41
   PubMed Web of Science ®Google Scholar
• Kanfer I, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. Pharmacotherapy 1993;13(pt 2):116S-28S
   PubMedGoogle Scholar
• Atrovent Nasal Spray [prescribing information]. Ridgefield, CT: Boehringer Ingleheim Pharmaceuticals, Inc, 2003. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020394s005lbl.pdf [Last accessed 3 June 2009]
   Google Scholar
• Wagenmann M, Naclerio RM. Complications of sinusitis. J Allergy Clin Immunol 1992;90(pt 2):552-4
   PubMedGoogle Scholar
• Mygind N, Borum P. Intranasal ipratropium: literature abstracts and comments. Rhinol Suppl 1989;9:37-44
   PubMedGoogle Scholar
• Borum P, Mygind N, Schultz Larsen F. Intranasal ipratropium: a new treatment for perennial rhinitis. Clin Otolaryngol Allied Sci 1979;4:407-11
   PubMed Web of Science ®Google Scholar
• Galant SP, Wilkinson R. Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options?. BioDrugs 2001;15:453-63
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Orgel HA, Biondi R, et al. Ipratropium nasal spray in children with perennial rhinitis. Ann Allergy Asthma Immunol 1997;78:485-91
   PubMed Web of Science ®Google Scholar
• James IGV, Campbell LM, Harrison JM, et al. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Curr Med Res Opin 2003;19:313-20
   PubMed Web of Science ®Google Scholar
• Meltzer EO, NasalCrom Study Group. Efficacy and patient satisfaction with cromolyn sodium nasal solution in the treatment of seasonal allergic rhinitis: a placebo-controlled study. Clin Ther 2002;24:942-52
   PubMed Web of Science ®Google Scholar
• Vermeulen J, Mercer M. Comparison of the efficacy and tolerability of topical levocabastine and sodium cromoglycate in the treatment of seasonal allergic rhinoconjunctivitis in children. Pediatr Allergy Immunol 1994;5:209-13
   PubMedGoogle Scholar
• Meltzer EO Allergic rhinitis: managing the pediatric spectrum. Allergy Asthma Proc 2006;27:2-8
   PubMed Web of Science ®Google Scholar
• Blaiss MS, Allergic Rhinitis in Schoolchildren Consensus Group. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin 2004;20:1937-52
   PubMed Web of Science ®Google Scholar
• Nayak A. A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin Pharmacother 2004;5:679-86
   PubMed Web of Science ®Google Scholar
• Nathan RA. Do leukotriene receptor antagonists have a place in pharmacotherapy of allergic rhinitis?. Ann Allergy Asthma Immunol 2003;90:466-8
   PubMed Web of Science ®Google Scholar
• van Adelsberg J, Philip G, LaForce CFet al., for the Montelukast Spring Rhinitis Investigator Group. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:214-22
   PubMed Web of Science ®Google Scholar
• van Adelsberg J, Philip G, Pedinoff AJet al., for the Montelukast Fall Rhinitis Study Group. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003;58:1268-76
   PubMed Web of Science ®Google Scholar
• Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002;88:592-600
   PubMed Web of Science ®Google Scholar
• Philip G, Malmstrom K, Hampel FCet al., for the Montelukast Spring Rhinitis Study Group. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-8
   PubMed Web of Science ®Google Scholar
• Kurowski M, Kuna P, Górski P. Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. Allergy 2004;59:280-8
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000;105:917-22
   PubMed Web of Science ®Google Scholar
• Chervinsky P, Philip G, Malice MP, et al. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol 2004;92:367-73
   PubMed Web of Science ®Google Scholar
• Borres MP, Bråkenhielm G, Irander K. How many teenagers think they have allergic rhinoconjunctivitis and what they do about it. Ann Allergy Asthma Immunol 1997;78:29-34
   PubMed Web of Science ®Google Scholar
• Mahadevia PJ, Shah S, Leibman C, et al. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: a conjoint analysis. Ann Allergy Asthma Immunol 2004;93:345-50
   PubMed Web of Science ®Google Scholar
• Stokes M, Amorosi SL, Thompson D, et al. Evaluation of patients’ preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg 2004;131:225-31
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Drugs. ‘Inactive’ ingredients in pharmaceutical products: update (subject review). Pediatrics 1997;99:268-78
   PubMed Web of Science ®Google Scholar
• Bogner RH, Wilkosz MF. Fast-dissolving tablets. US Pharmacist, 2002. Available at: http://www.uspharmacist.com/oldformat.asp?url=newlook/files/feat/fastdissovling.htm [Last accessed 24 April 2009]
   Google Scholar
• Reig AR, Fernandez MJP, Cervera JG, et al. Acceptance survey of a fast dissolving tablet pharmaceutical formulation in allergic patients. Satisfaction and expectances. Allergol et Immunopathol 2006;34:107-12
   PubMedGoogle Scholar
• Fineman SM. Clinical experience with azelastine nasal spray in children: physician survey of case reports. Pediatr Asthma Allergy Immunol 2001;15:49-54
   Google Scholar
• Roberts KR, Linder L, Sund ML. Glucose incorporation by human dental plaque bacteria. Caries Res 1981;15:492-500
   PubMed Web of Science ®Google Scholar
• Olmez S, Uzamis M, Erdem G. Association between early childhood caries and clinical, microbiological, oral hygiene and dietary variables in rural Turkish children. Turk J Pediatr 2003;45:231-6
   PubMed Web of Science ®Google Scholar
• Durward C, Thou T. Dental caries and sugar-containing liquid medicines for children in New Zealand. New Zealand Dental Journal 1997;93:124-9
   PubMedGoogle Scholar
• Maguire A, Rugg-Gunn AJ, Butler TJ. Dental health of children taking antimicrobial and non-antimicrobial liquid oral medication long-term. Caries Res 1996;30:16-21
   PubMed Web of Science ®Google Scholar
• Shaw L, Glenwright HD. The role of medications in dental caries formation: need for sugar-free medication for children. Pediatrician 1989;16:153-5
   PubMedGoogle Scholar
• European Commission. Guidelines, Volume 3B – Medicinal Products for Human Use. Excipients in the label and package leaflet of medicinal products for human use, July 2003
   Google Scholar
• Aerius Summary of Product Characteristics. Brussels, Belgium: SP Europe, 2007. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/aerius/H-313-PI-en.pdf [Last accessed 3 June 2009]
   Google Scholar
• Allegra® (fexofenadine hydrochloride) prescribing information. sanofi-aventis U.S. LLC, Bridgewater, NJ, USA, 2007. Available at: http://products.sanofi-aventis.us/allegra/allegra.html [Last accessed 3 June 2009]
   Google Scholar
• Neoclarityn Summary of Product Characteristics. Brussels, Belgium: SP Europe, January 2008. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/neoclarityn/H-314-PI-en.pdf [Last accessed 3 June 2009]
   Google Scholar
• Xyzal® (levocetirizine dihydrochloride) 0.5 mg/ml oral solution. UCB Pharma Ltd., Slough, UK, January 2008. Available at: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?format=original&documentid=19876 [Last accessed 3 June 2009]
   Google Scholar
• Benadryl. Available at: www.benadrylusa.com [Last accessed 3 June 2009]
   Google Scholar
• Children's Claritin Fruit Flavored Syrup. Available at: http://www.claritin.com/pdf/readthebox/claritin_child_fruit.pdf [Last accessed 3 June 2009]
   Google Scholar
• Children's Claritin Grape Flavored Syrup. Available at: http://www.claritin.com/pdf/readthebox/claritin_child_grape.pdf [Last accessed 3 June 2009]
   Google Scholar
• Dimetapp Children's Cold and Allergy Elixir. Available at: http://www.dimetapp.com/cold/rsn_caelixir.asp [Last accessed 3 June 2009]
   Google Scholar
• Piriteze Allergy Syrup. Available at: http://www.piriton.co.uk/Piriteze_Allergy_Syrup.htm [Last accessed 3 June 2009]
   Google Scholar
• Piriton Syrup. Available at: http://www.piriton.co.uk/Piriton_Syrup.htm [Last accessed 3 June 2009]
   Google Scholar
• Triaminic Cold and Allergy Liquid. Available at: http://www.triaminic.com/us_en/products/20604CR_ingredients.shtml [Last accessed 3 June 2009]
   Google Scholar
• Tylenol Children's Cold & Allergy Plus Oral Suspension. Available at: http://www.tylenol.com/product_detail.jhtml?id=tylenol/children/prod_cca.inc&prod=subpcca# [Last accessed 3 June 2009]
   Google Scholar
• Tylenol Children's Cough and Runny Nose Plus Oral Suspension. Available at: http://www.tylenol.com/product_detail.jhtml?id=tylenol/children/prod_coughrunnose.inc&prod=child_coughrunnose# [Last accessed 3 June 2009]
   Google Scholar
• Children's Zyrtec Allergy Syrup. Available at: http://www.zyrtec.com/econsumer/zyrtec/product.view?body=/zyrtec/pages/prod_children.jsp&s=prod_children&p&t [Last accessed 3 June 2009]
   Google Scholar
• Peres KG, Oliveira CT, Peres MA et al. Sugar content in liquid oral medicines for children. Rev Saúde Pública 2005;39:486-9
   Google Scholar
• Mackie IC, Bentley E. Sugar-containing or sugar-free paediatric medicines: does it really matter?. Dent Update 1994;21:192-4
   PubMedGoogle Scholar
• Department of Health, Report on Health & Social Subjects No 37 Dietary Sugars and Human Disease. Report of the Panel on Dietary Sugars, Committee on Medical Aspects of Food Policy. London: HMSO, 1989
   Google Scholar
• American Dental Association Position Statement. Role of sugar-free foods and medications in maintaining good oral health. November 1, 1999. Available at: http://www.ada.org/prof/resources/positions/statements/sugarfre.asp [Last accessed 3 June 2009]
   Google Scholar
• Scottish Intercollegiate Guidelines Network. Section 5.4: Sugar-free medicines. In: Targeted Prevention of Dental Caries in the Permanent Teeth of 6-16 Year Olds Presenting for Dental Care. Edinburgh, Scotland: SIGN, 2000. Available at: http://www.sign.ac.uk/pdf/sign47.pdf [Last accessed 3 June 2009]
   Google Scholar
• Grabitske HA, Slavin JL. Gastrointestinal effects of low-digestible carbohydrates. Crit Rev Food Sci Nut 2009;49:327-60
   PubMed Web of Science ®Google Scholar
• Oku T, Nakamura S. Threshold for transitory diarrhea induced by ingestion of xylitol and lactitol in young male and female adults. J Nutr Sci Vitaminol (Tokyo) 2007;53:13-20
   PubMed Web of Science ®Google Scholar
• Storey D, Lee A, Bornet F, et al. Gastrointestinal tolerance of erythritol and xylitol ingested in a liquid. Eur J Clin Nutr 2007;61:349-54
   PubMed Web of Science ®Google Scholar
• Bateman B, Warner JO, Hutchinson E, et al. The effects of a double blind, placebo controlled, artificial food colorings and benzoate preservative challenge on hyperactivity in a general population sample of preschool children. Arch Dis Child 2004;89:506-11
   PubMed Web of Science ®Google Scholar
• Artificial sweeteners: no calories…sweet! FDA Consumer Magazine July/August 2006. Available at: http://www.fda.gov/fdac/features/2006/406_sweeteners.html [Last accessed 3 June 2009]
   Google Scholar
• Koppel BS, Harden CL, Daras M. Tegretol excipient-induced allergy. Arch Neurol 1991;48:789
   PubMed Web of Science ®Google Scholar
• Weber RW, Hoffman M, Raine DA Jr, et al. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol 1979;64:32-7
   PubMed Web of Science ®Google Scholar
• Chafee FH, Settipane GA. Asthma caused by FD&C approved dyes. J Allergy 1967;40:65-72
   PubMedGoogle Scholar
• Larsen WG. Cosmetic dermatitis due to a dye (D&C Yellow #11). Contact Dermatitis 1975;1:61
   PubMedGoogle Scholar
• Castelain PY, Piriou A. Photosensitization eczema with positive erythrosine test. Contact Dermatitis 1978;4:305
   PubMed Web of Science ®Google Scholar
• Fisherman EW, Cohen GN. Aspirin and other cross-reacting small chemicals in known aspirin intolerant patients. Ann Allergy 1973;31:476-84
   PubMedGoogle Scholar
• Mancuso G, Staffa M, Errani A, et al. Occupational dermatitis in animal feed mill workers. Contact Dermatitis 1990;22:37-41
   PubMed Web of Science ®Google Scholar
• Supramaniam G, Warner JO. Artificial food additive intolerance in patients with angio-oedema and urticaria. Lancet 1986;2:907-9
   PubMed Web of Science ®Google Scholar
• Michaelsson G, Juhlin L. Urticaria induced by preservatives and dye additives in food and drugs. Br J Dermatol 1973;88:525-32
   PubMed Web of Science ®Google Scholar
• Michaelsson G, Pettersson L, Juhlin L. Purpura caused by food and drug additives. Arch Dermatol 1974;109:49-52
   PubMed Web of Science ®Google Scholar
• Bell T. Colourants and drug reactions. Lancet 1991;338:55-6
   PubMed Web of Science ®Google Scholar
• Gross PA, Lance K, Whitlock RJ, et al. Additive allergy: allergic gastroenteritis due to Yellow Dye #6. Ann Intern Med 1989;111:87-8
   PubMed Web of Science ®Google Scholar
• Jenkins P, Michaelsson R, Emerson PA. Adverse drug reaction to sunset-yellow in rifampicin isoniazid tablet. Lancet 1982;2:385
   PubMed Web of Science ®Google Scholar
• Desmond RE, Trautlein JJ. Tartrazine (FD&C Yellow #5) anaphylaxis: a case report. Ann Allergy 1981;46:81-2
   PubMedGoogle Scholar
• Trautlein JJ, Mann WJ. Anaphylactic shock caused by yellow dye (FD&C No 5 and FD&C No 6) in an enema (case report). Ann Allergy 1978;41:28-9
   PubMedGoogle Scholar
• Lockey SD Sr. Hypersensitivity to tartrazine (FD&C Yellow No. 5) and other dyes and additives present in foods and pharmaceutical products. Ann Allergy 1977;38:206-10
   PubMedGoogle Scholar
• Parodi G, Parodi A, Rebora A. Purpuric vasculitis due to tartrazine. Dermatologica 1985;171:623
   Google Scholar
• Criep LH. Allergic vascular purpura. J Allergy 1971;48:7-12
   Google Scholar
• Bell RT, Fishman S. Eosinophilia from food dye added to enteral feeding. N Engl J Med 1990;322:1822
   PubMed Web of Science ®Google Scholar
• Baungardner DJ. Persistent urticaria caused by a common coloring agent. Postgrad Med 1989;85:265-6
   PubMed Web of Science ®Google Scholar
• Pohl R, Balon R, Berchou R, et al. Allergy to tartrazine in antidepressants. Am J Psychiatry 1987;144:237-8
   PubMed Web of Science ®Google Scholar
• Stevenson DD, Simon RA, Lumry WR, et al. Adverse reactions to tartrazine. J Allergy Clin Immunol 1986;78:182-91
   PubMed Web of Science ®Google Scholar
• Morales MC, Basomba A, Pelaez A, et al. Challenge tests with tartrazine in patients with asthma associated with intolerance to analgesics (ASA-triad): a comparative study with placebo. Clin Allergy 1985;15:55-9
   PubMedGoogle Scholar
• Hariparsad D, Wilson N, Dixon C, et al. Oral tartrazine challenge in childhood asthma: effect on bronchial reactivity. Clin Allergy 1984;14:81-5
   PubMedGoogle Scholar
• Settipane GA. Adverse reactions of aspirin and related drugs. Arch Intern Med 1981;141:328-32
   PubMed Web of Science ®Google Scholar
• Spector SL, Wangaard CH, Farr RS. Aspirin and concomitant idiosyncrasies in adult asthmatic patients. J Allergy Clin Immunol 1979;64:500-6
   PubMed Web of Science ®Google Scholar
• Juhlin L, Michaelsson G, Zetterstrom O. Urticaria and asthma induced by food-and-drug additives in patients with aspirin hypersensitivity. J Allergy Clin Immunol 1972;50:92-8
   PubMed Web of Science ®Google Scholar
• McCann D, Barrett A, Cooper A, et al. Food additives and hyperactive behavior in 3-year-old and 8/9-year-old children in the community: a randomized, double-blinded, placebo-controlled trial. Lancet 2007;370:1560-7
   PubMed Web of Science ®Google Scholar
• Rowe KS, Rowe KJ. Synthetic food coloring and behavior: a dose response effect in a double-blind, placebo-controlled, repeated-measures study. J Pediatr 1994;125:691-8
   PubMed Web of Science ®Google Scholar
• Thorley G. Pilot study to assess behavioural and cognitive effects of artificial food colours in a group of retarded children. Dev Med Child Neurol 1984;26:56-61
   PubMed Web of Science ®Google Scholar
• Adams W. Lack of behavioral effects from Feingold diet violations. Percept Mot Skills 1981;52:307-13
   PubMed Web of Science ®Google Scholar
• Mattes JA, Gittleman R. Effects of artificial food colorings in children with hyperactive symptoms: a critical review and results of a controlled study. Arch Gen Psychiatry 1981;38:714-18
   PubMed Web of Science ®Google Scholar
• Hastings G, Hughes K, Lowry R. Promoting sugar-free medicines: parents’ view. Br J Gen Pract 1997;47:823-4
   PubMed Web of Science ®Google Scholar
• Hunter ML, Lewis R, Hunter B. Consumer demand in the purchase and prescription of sugar-free medicines. Int J Paediatr Dent 2000;10:140-4
   PubMedGoogle Scholar
• Bentley EM, Mackie IC. A qualitative investigation into general medical practitioners’ prescribing habits prior to a dental health education campaign. Health Education Research 1993;8:519-24
   Web of Science ®Google Scholar
• Bradley M, Kinirons MJ. Provision of sugar-free medicines for young children: the views of a sample of parents in Northern Ireland. J Ir Dent Assoc 1998;44:70-3
   PubMedGoogle Scholar
• McVeigh N, Kinirons MJ. Pharmacists’ knowledge, attitudes and practices concerning sugar-free medicines. Int J Paediatr Dent 1999;9:31-5
   PubMedGoogle Scholar